It’s been announced today that the UK medicines watchdog – The Medicines and Healthcare products Regulatory Agency (MHRA) – has ruled that Pseudoephedrine and ephedrine-containing medicines will not be reclassified as prescription drugs. The MHRA has decided to retain the drugs’ pharmacy (P) classification after two years of monitoring the impact of tougher sales restrictions.
PRimage client, The Company Chemists’ Association has issued the following press comment in response to the announcement:
Rob Darracott, CEO of the Company Chemists’ Association (CCA), said: “The MHRA decision shows real confidence in pharmacy’s ability to control sales of pseudoephedrine, which can be used in the home manufacture of class A drug crystal meth (methylamphetamine). Pharmacy has stepped up to ensure tighter sales controls, such as restricting purchases to one pack per customer. It shows what pharmacy can do when we work as a team.”